Clinical Trial

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

Name: Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 — clinical trial record (NCT04637282)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.

Protocol Amendment History 11 amendments

This ClinicalTrials.gov record has been amended 11 times since 2020-11-14; most recent amendment 2026-05-06.

Trial Details

NCT Number	NCT04637282
Lead Sponsor	Polaryx Therapeutics, Inc.
Conditions	Juvenile Neuronal Ceroid Lipofuscinosis
Enrollment	39 participants
Start Date	2026-11-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-08